Treatment of ALK+ Non–Small Cell Lung Cancer in the Brazilian Public and Private Health Care Systems: A Tale of Inequalities (LACOG/GBOT 1918)

PURPOSEALK rearrangements occur in 5.4% of Brazilian patients with non–small cell lung cancer (NSCLC). Data on treatment patterns, access to ALK inhibitors, and survival outcomes are scarce.MATERIALS AND METHODSLACOG/GBOT 1918 is a retrospective, observational study that included patients diagnosed...

Повний опис

Збережено в:

Бібліографічні деталі
Автори:	Eldsamira Mascarenhas, Ana C. Z. Gelatti, Tatiane Montella, Marcelo Corassa, William N. William, Rosely Yamamura, Clarissa Baldotto, Eduardo H. Cronemberger, Aknar F. C. Calabrich, Giuliano S. Borges, Carlos H. A. Teixeira, Danielli Matias, Aline F. Fares, Cristina D. A. T. Sampaio, Antonia Angeli Gazola, Francisco de C. Zuanazzi, Paulo A. C. Schulze, Luísa M. T. Franche, Rafaela G. de Jesus, Juliana Giacomazzi, Matheus S. Rocha, Gustavo Gössling, Carlos G. Ferreira
Формат:	Artigo
Мова:	Inglês
Опубліковано:	American Society of Clinical Oncology 2026-06-01
Серія:	JCO Global Oncology
Онлайн доступ:	https://ascopubs.org/doi/10.1200/GO-26-00042
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!

Treatment of ALK+ Non–Small Cell Lung Cancer in the Brazilian Public and Private Health Care Systems: A Tale of Inequalities (LACOG/GBOT 1918)

Схожі ресурси